# A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

> **NCT04212013** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04212013
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-23
- **Primary completion:** 2027-03-18
- **Final completion:** 2027-03-18
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212013, "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04212013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*